European shares edged lower on Thursday after the US Federal Reserve quashed hopes of interest rates cuts.
Wall Street edged lower on Thursday, led by a decline in energy stocks, as the US Federal Reserve now was seen as less likely to cut interest rates.
The dollar index, which measures the Greenback against a basket of major currencies, and bond yields strengthened for a second day on Thursday, as the US Federal Reserve dampened rate cut bets.
Global stocks edged lower for a second consecutive trading session on Thursday, as the US Federal Reserve dampened interest rates cut bets.
Tesla made issues of the company's new shares and more than $2B worth debt, sending shares more than 5% up, as the CEO Elon Musk announced the plan to raise capital.
DowDuPont reported a 28% decrease in adjusted profit for the quarter, affected by weaker chemical demand, sending the company's shares down 1% to $37.06 in pre-market trading.
Kellogg stated it will replace the company's CFO, and reported a 36.5 % drop in first-quarter earnings amid higher costs and the strong USD, sending shares 5% down pre-market trading.
New orders for the US-made goods increased the most in seven months, rebounding 1.9% in March due to solid demand for transportation equipment.
Volkswagen shrug off a €1B legal charge to meet the Q1 operating profit forecast, sending the company's shares 4.5% higher, thanks to higher-margin sport cars' sales and cost cuts.
The US worker productivity grew at the fastest pace since 2014 in the Q1, depressing labour costs and suggesting that consumer price growth would remain benign.
Barclays investor Edward Bramson announced on Thursday that he has failed at gaining a board seat at the bank. The investor intended to overhaul the bank.
On Thursday, worker's unions in Belfast revealed that Bombardier has announced a plan to sell its production plant in the city, which employs more than 3,600 people.
Despite the initial decline of US stocks caused by the surge of the USD that was initiated by US monetary policy, by the middle of Thursday's London session US stock futures began to climb.
On Thursday, the Bank of England made a rate announcement, revealed the size of their asset purchase program and future forecasts. In general, monetary policy in the UK remained unchanged.
On Thursday, ARA US Hospitality has started its Singaporean initial public offering with the intention to raise around $451M with a portfolio of 38 US hotels and an offer price of 88 cents per share.
India's hotel start-up OYO is set to acquire the EU vacation rental firm @Leisure in a €370M deal with the German media group Axel Springer, other shareholders, with a transaction to be completed already in June.
On Thursday, crude oil price benchmarks declined. The main reason for the decline was the surge of the US Dollar. Meanwhile, some financial media blamed US production for the fall of the prices.
By the middle of Thursday's London session the US Dollar was regaining value after experiencing a sharp drop on Wednesday due to a monetary policy announcement. As the value of the measure, namely, the USD grew, stock price indices declined.
Australia's retail conglomerate Wesfarmers made a proposal worth A$776M to acquire Kidman Resources, the local lithium miner, as it seeks to deepen exposures to the high-tech minerals.
On Thursday, Villa World, Australia's property developer has got a sweetened takeover bid from the Australian property development business AVID Property Group, which now gives it a market valuation of A$293.5M.
On Thursday, Thomas Cook set May 7 as a deadline for interest expressions in the airline business, with Lufthansa and Indigo Partners among the potential bidders.
Watches of Switzerland, the private equity-owned group, stated on Thursday it is exploring a London listing of its stock market, as it seeks for acquisition deals in the United States.
On Thursday, the UK aero-engine maker Rolls-Royce stated it is set to meet the full-year profit and cash forecasts, after it managed to fix the issues related to its Trent 1000 fleet.
The UK drugmaker AstraZeneca tied up with the French biopharmaceutical company Transgene by signing a deal on Thursday to develop five viral immunotherapies aimed at killing cancer.